| 5.47 0.4 (7.89%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.56  |
1-year : | 9.12 |
| Resists | First : | 6.47 |
Second : | 7.8 |
| Pivot price | 5.12 |
|||
| Supports | First : | 4.32 | Second : | 3.59 |
| MAs | MA(5) : | 4.92 |
MA(20) : | 5.23 |
| MA(100) : | 7.64 |
MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 52.6 |
D(3) : | 28.4 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 13.69 | Low : | 4.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALVO ] has closed below upper band by 16.9%. Bollinger Bands are 36.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.5 - 5.53 | 5.53 - 5.55 |
| Low: | 5.05 - 5.07 | 5.07 - 5.09 |
| Close: | 5.43 - 5.47 | 5.47 - 5.51 |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Sat, 06 Dec 2025
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
Sat, 06 Dec 2025
Alvotech (NASDAQ:ALVO) Stock Price Up 6.3% - Here's What Happened - MarketBeat
Sat, 06 Dec 2025
Alvotech (NasdaqGM:ALVO): Assessing Valuation After European Approval of Denosumab Biosimilar AVT03 - simplywall.st
Sat, 06 Dec 2025
Alvotech (ICSE:ALVO) Price Target Decreased by 17.29% to 1,165.86 - Nasdaq
Fri, 05 Dec 2025
Oaktree Capital Management LP Trims Position in Alvotech $ALVO - MarketBeat
Fri, 05 Dec 2025
How Investors Are Reacting To Alvotech (ALVO) EU Approval Of AVT03 Denosumab Biosimilar - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 312 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 61.7 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 2,730 (K) |
| Shares Short P.Month | 1,660 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.59 |
| Profit Margin | 12.1 % |
| Operating Margin | -2.7 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 10.6 % |
| Gross Profit (p.s.) | 1.02 |
| Sales Per Share | 1.84 |
| EBITDA (p.s.) | 0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | 23.78 |
| PEG Ratio | 0 |
| Price to Book value | -9.28 |
| Price to Sales | 2.97 |
| Price to Cash Flow | -64.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|